A newly approved drug for type 2 diabetes and kidney disease, sotagliflozin, has shown remarkable benefits in reducing the ...

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...

Less than 5% of hospitalized adults with type 2 diabetes received an SGLT2 inhibitor or GLP-1 before being discharged, ...

Consultant in endocrinology and diabetes Professor Vinod Patel discusses current recommended pharmacological treatment ...

The results showed that people who took sotagliflozin had a 23% lower risk of heart attacks, strokes, and death from ...

The deaths are also partly the result of medical successes: People are living longer, and more people are surviving heart ...

The medication, known as sodium-glucose co-transporter 2 inhibitors (SGLT2is), is already used to lower blood sugar in people ...

Sotagliflozin, a drug for diabetes and kidney disease, offers significant protection against heart attacks and strokes by ...

Congestive heart failure (CHF) and heart failure are the same thing. Both terms describe the inability of the heart to pump enough blood to service the body's needs. The term "congestive" simply ...

A new study found that a drug recently approved to treat type 2 diabetes and kidney disease in patients with additional ...

A team of researchers, led by one of Indian origin, has found that a drug recently approved by the US Food and Drug Administration (FDA) to treat type 2 diabetes can also reduce heart attacks and ...

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...